Hidantin

Quick links to important sections

Hidantin

Method of action: Antiepileptic

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hidantin

Property Description
Active ingredient Phenytoin / Phenytoin sodium
Form Capsules, Chewable tablets, Oral suspension, Parenteral solution
Pharmacological class Antiepileptic drug (Anticonvulsant)
General purpose Stabilizes abnormal electrical activity in the nervous system
Origin Synthetic, Hydantoin derivative

What Type of Medicine is Hidantin?

Hidantin is a synthetic, prescription-only medication primarily classified as an antiepileptic drug, universally known as an anticonvulsant. Its core substance is the active ingredient Phenytoin, a well-established compound chemically categorized as a hydantoin derivative. This classification places Phenytoin within a foundational sub-class of anti-seizure agents. Phenytoin is used for managing conditions characterized by abnormal neural excitability. The medication is also categorized as a Class IB antiarrhythmic agent, as it has the capability to influence certain electrical activities in the heart.

Composition and Available Forms of Phenytoin

The essence of this medication is Phenytoin or its salt, Phenytoin sodium, formulated as a single active ingredient product. Hidantin is manufactured in several dosage forms to facilitate its administration via both the oral and intravenous routes of administration. Oral preparations include capsules (including specialized extended-release forms that allow for sustained action), chewable tablets, and an oral suspension. For acute management, a sterile parenteral solution is available for direct intravenous administration, often employed in hospital settings for rapid control. The availability of these multiple preparations, including formulations specifically suited for pediatric and adult patients, ensures the drug can be consistently and flexibly delivered across various clinical needs.

General Purpose: Why is Hidantin Used?

The overarching general purpose of Hidantin is to stabilize the electrical activity of the nerve cells in the central nervous system, effectively preventing the initiation and spread of uncontrolled electrical impulses. This stabilizing action helps to maintain a consistent threshold against hyperexcitability, which is essential for controlling seizures. Its membrane-stabilizing influence is also leveraged to provide therapeutic benefit in managing specific cardiac conditions characterized by unstable electrical conduction.

Regulatory References

  1. Phenytoin: MedlinePlus Drug Information
  2. Phenytoin - StatPearls - NCBI

What side effects are possible with Hidantin?

Possible Side Effects and Safety Information

The official safety profile for Phenytoin (Hidantin) organizes adverse reactions into categories based on affected organ systems and frequency, as documented by regulatory agencies.

Common Adverse Reactions and System-Organ Classes The most frequently reported effects are generally dose-related and classified under Nervous System Disorders. These commonly include nystagmus (involuntary eye movement), ataxia (loss of coordination), slurred speech, and mental confusion. Gingival hyperplasia (gum overgrowth) is also a common reaction, often associated with long-term use. Other affected systems include Gastrointestinal (nausea, vomiting) and Skin and Subcutaneous Tissue (various rashes).

Serious and Clinically Significant Safety Concerns Regulatory documents highlight the risk of rare but serious reactions, categorized as Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Other severe, documented risks involve Blood and Lymphatic System Disorders (e.g., aplastic anemia, agranulocytosis) and Hepatobiliary Disorders (acute liver failure). Cardiovascular events, including severe hypotension and cardiac arrest, are noted as risks during rapid intravenous administration, particularly in vulnerable patients.

Population and Exposure Notes Safety statements address risks for specific groups, such as the increased risk of SJS/TEN in certain Asian ancestries with the *HLA-B1502 allele. Prenatal exposure is associated with congenital malformations. The risk of CNS effects is often highest at treatment initiation, while effects on bone mineral density are associated with prolonged therapy. Phenytoin is noted to potentially aggravate** certain seizure types, such as absence seizures, and abrupt discontinuation may lead to increased seizure frequency.

Overdose and Emergency Response

Overdose and when to seek help

The overdose profile for Hidantin (Phenytoin) is officially documented by regulatory authorities, detailing both common signs of toxicity and severe life-threatening outcomes. The initial manifestations of toxicity are primarily neurological and often involve cerebellar function, including the documented presence of nystagmus, ataxia, and slurred speech (dysarthria).

As exposure increases, the risks escalate to severe systemic outcomes such as coma, respiratory depression, and cardiovascular collapse, with official labeling noting the potential for fatal outcomes. Due to these severe risks, regulatory guidance mandates that individuals must seek immediate medical attention upon suspicion of overdose and contact a poison control center.

Treatment is strictly symptomatic and supportive, as official sources explicitly state that no specific antidote is known. Management procedures documented in prescribing information include the requirement for intensive monitoring, particularly of ECG and blood pressure. Furthermore, regulatory texts note that rapid intravenous administration is an exposure factor associated with an increased risk of severe cardiac toxicity, and patients with hepatic impairment may face increased toxicity risk.

Therapeutic Uses of Hidantin

Hidantin (Phenytoin) is indicated for the control of certain types of seizures and for the treatment or prevention of seizures that may occur during or after surgery to the brain or nervous system. The focus is on providing supportive relief in conditions where functional stability becomes affected.


What Hidantin Treats: Main Uses and Benefits

Hidantin is commonly used for the long-term management of epilepsy, applied across conditions characterized by recurrent or episodic manifestations. It is relevant for easing symptoms of increased neurological or muscular activity, specifically addressing generalized tonic-clonic seizures and complex partial seizures.

The key therapeutic benefit is that it contributes to supporting stability and helps ease the overall symptom load associated with these recurrent episodes, assisting with maintaining functional stability. The medication also plays a role in clinical settings that involve acute or unstable symptom patterns, such as the rapid management of Status Epilepticus and the prevention of seizure onset following neurosurgery. In specialized cases, it may be part of symptomatic management for certain ventricular arrhythmias linked to cardiac glycoside toxicity.

“The primary goal of this therapy is to support the patient during difficult episodes by easing the associated symptomatic distress and helping them cope more steadily with symptom fluctuations.”

Quick Fact: Relief for Seizure Activity Hidantin is applied when symptoms create noticeable functional strain, and is relevant for easing symptoms that create noticeable physiological strain.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Contraindicated Populations

The medicine must not be used by patients with specific medical conditions, as defined by official regulatory documents. Absolute prohibitions include a known history of hypersensitivity to phenytoin or other hydantoins, or a prior history of acute hepatotoxicity clearly linked to the medicine. Additionally, it is contraindicated in patients with severe, pre-existing cardiac electrical defects such as Sino-atrial block and Adams-Stokes Syndrome, as well as in patients concurrently using the antiretroviral drug delavirdine.

Restricted Use and Non-Eligibility

Official labeling defines several conditions requiring caution. Patients with hepatic or renal impairment may use the medicine, but only under restricted circumstances where monitoring of unbound (free) phenytoin concentrations is mandatory. Furthermore, Hidantin is not effective for, and may potentially aggravate, Absence seizures and Myoclonic seizures, defining ineligibility for these specific seizure types.

Age and Pregnancy Restrictions

Use during pregnancy is generally not recommended due to the risk of fetal harm, and effective contraception is required for women of childbearing potential. In older adults, use is permitted, but lower or less frequent dosing is often necessary due to altered drug clearance. Pediatric use is established for approved seizure types, but requires careful specialized monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Hidantin (Phenytoin) is known to be involved in clinically significant drug–drug and drug–substance interaction patterns as documented in official regulatory labeling. These interactions are primarily classified as pharmacokinetic due to the drug’s metabolic profile.

Phenytoin acts as a potent inducer of several hepatic drug-metabolizing enzymes, including CYP3A4 and CYP2C9. Co-administration with other medicines metabolized by these enzymes often leads to accelerated clearance and a resulting decreased exposure of the co-administered drug. Conversely, Phenytoin is a substrate for CYP2C9 and CYP2C19; therefore, enzyme inhibitors (such as certain antibiotics or antifungals) may significantly increase phenytoin serum concentrations.

Regulatory sources define strict constraints, including the contraindicated combination of Phenytoin with Delavirdine. Additionally, mandatory timing rules apply to non-medicinal substances: it is officially suggested that the drug not be administered concomitantly with enteral feeding preparations as co-administration is associated with lower-than-expected Phenytoin levels.

The official label also documents bi-directional effects with alcohol: acute consumption may increase Phenytoin levels, while chronic consumption may decrease them. Furthermore, population-specific notes indicate that hepatic impairment or hypoalbuminemia increase the fraction of unbound Phenytoin, complicating the interpretation of total plasma concentrations.

Mechanism of Action

Voltage-Gated Sodium Channel Blockade

Phenytoin's primary mechanism involves the precise use-dependent blockade of voltage-gated sodium channels ( NaV) in neuronal and cardiac membranes. The drug binds selectively to the channel when it is in its inactivated state, thereby inhibiting the rapid flow of positive sodium ions ( Na^+) into the cell. This binding is enhanced by high-frequency electrical activity, making the mechanism most relevant in highly active tissue. The resulting physiological effect is a reduction in excitability of the cell membrane, limiting its responsiveness to repeated electrical stimulation.

Limitation of High-Frequency Neural Signaling

By stabilizing the sodium channels in the inactivated state, the drug significantly prolongs the refractory period—the time during which a neuron is incapable of generating a new action potential. This targeted modulation limits the ability of an initial high-frequency electrical impulse to recruit adjacent neurons and inhibits the spread of synchronized electrical activity across the central nervous system. This action is a core mechanism for regulating the overall excitability of neural circuits.

Dual-Tissue Electrical Modulation

This mechanism also extends to the heart, where Phenytoin functions as a Class IB antiarrhythmic agent. It shortens the action potential duration in cardiac tissue and can modulate the cardiac Ryanodine Receptor ( RyR2). This dual action on both neuronal and cardiac excitable tissue results in a comprehensive physiological consequence, increasing the threshold against the propagation of electrical activity in two different organ systems.

Dosage and Administration Information

Official Administration Guidelines

Hidantin (Phenytoin) follows established procedural guidelines that define both the method of administration and the scheduling of doses. The Route of administration is primarily Oral for chronic, long-term maintenance, utilizing available forms such as capsules and oral suspension. The Intravenous (IV) route is utilized for acute management, such as rapid loading in a clinical setting.

In terms of Dosing schedule, adult maintenance therapy typically starts at 300 mg daily (administered once daily for extended-release forms or in divided doses) and adheres to a daily range of 200 mg to 500 mg. A Frequency and schedule constraint requires that dose adjustments be separated by 7 to 10 days to allow the drug to reach a stable concentration in the body.

Special procedural conditions apply to the IV route: the parenteral solution is diluted in normal saline (avoiding dextrose) and infused at a maximum rate not exceeding 50 mg per minute in adults. Furthermore, the IV site is flushed with sterile saline both before and after the injection. Age-group administration rules include weight-based dosing for pediatric patients, while older adults may require lower or less frequent dosing due to altered physiological clearance.

Connection to the overall use protocol

The clinical protocol describes a procedural duality for the medication: one set of precise rules governs rapid IV administration in acute settings, focusing on specific rate and dilution requirements, while a separate set of rules applies to chronic oral therapy, emphasizing specific daily dose ranges and mandatory time-interval protocols for adjustment. This structure ensures that both emergency and long-term applications are standardized.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Hidantin (Phenytoin)

Research focused on Hidantin primarily stems from Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews spanning several decades. These studies have explored the drug in the context of long-term management for both generalized tonic-clonic seizures and complex partial seizures.

For the long-term management of seizures, researchers primarily examined the time elapsed before the first seizure recurrence and the proportion of patients achieving long seizure-free periods (remission, e.g., 12 months). Findings describe patterns of patient retention and measured changes in seizure frequency over study periods typically lasting 6 to 12 months. However, a significant portion of this foundational evidence is older. This means that while studies contribute to understanding symptom patterns, the scientific literature notes that evidence quality may vary across studies compared to contemporary clinical trials.

In acute care, Hidantin has been evaluated in comparative trials as a second-line intervention for convulsive status epilepticus. The main outcome studied was the measurement of cessation of seizure activity within a short time frame. Scientific reviews indicate that the certainty of the evidence for this acute use is often described as low to very low due to methodological difficulties and the complexity of conducting research in emergency settings.

Research has also explored the drug in special populations, including children and older adults. Studies monitor outcomes relative to cognitive performance in children and describe a pattern related to reduced drug clearance in older adults. Despite the long history of use, comparative evidence against the latest therapies is lacking in some areas, and the overall impact of individual genetic variability on outcomes is not yet clearly established in prospective studies.

Key Studies & References

  1. Phenytoin Drug Information (MedlinePlus)
  2. Clinical Guideline: Antiepileptic drug treatment for children and young people with epilepsy

Frequently Asked Questions (FAQ)

Common questions about Hidantin (FAQ)


Q: Does Hidantin work immediately, or does it take time to notice effects?

Official administration guidelines indicate that dose adjustments must be separated by 7 to 10 days. This time is required to ensure the medication reaches a stable concentration in the bloodstream. Because of this, a patient may not experience the full clinical effects immediately.


Q: Can taking Hidantin cause changes in mood or make you feel different emotionally?

Official safety documents list nervous system effects such as mental confusion as common side effects. However, a specific mention of changes in mood, depression, or other emotional shifts is not consistently highlighted in regulatory texts. If a patient experiences unexpected emotional changes, such symptoms are generally addressed by a healthcare provider.


Q: How does Hidantin affect birth control pills or other hormonal medications?

Regulatory sources describe Hidantin as a potent inducer of certain drug-metabolizing enzymes in the liver. This can lead to the accelerated breakdown and decreased exposure of other co-administered medications, including hormonal contraceptives (birth control pills). This metabolic interaction may be associated with reduced effectiveness of these hormonal medicines.


Q: Can older adults expect different side effects from Hidantin compared to younger patients?

Official information indicates that older adults may require lower or less frequent dosing due to altered drug clearance, which affects how the body eliminates the medication. The difference in clearance is associated with the requirement for lower or less frequent dosing to manage blood concentrations.


Q: What does it mean if my doctor mentions a 'loading dose' for Hidantin?

The term 'rapid loading' is used in official administration guidelines to describe a specific procedure for acute management in a clinical setting. A loading dose is defined as a higher initial amount of the drug given to quickly raise the medication's level in the blood. This allows the therapeutic concentration to be reached sooner than with standard oral maintenance dosing.


Q: Why is it necessary to take Vitamin D or calcium supplements while on Hidantin?

Official safety warnings note that prolonged therapy with this medication is associated with effects on bone mineral density. This means that, over time, the drug can potentially impact bone health. Consultation with a healthcare provider may address the need for supplements to help support bone density.


Q: Is it safe to drive or operate machinery while taking this medication?

Official patient information explicitly states that Hidantin can impair a person's ability to perform tasks that require mental alertness, such as driving or operating heavy machinery. This is due to potential nervous system side effects like dizziness or lack of coordination. Discussions about this risk are generally held with a healthcare provider.


Q: Why do doctors need to check blood levels so often when a person is on Hidantin?

Regulatory guidelines require blood tests because Hidantin is cleared by the body slowly and in a nonlinear way, meaning that small changes in dose can cause disproportionately large increases in the drug's blood level. Frequent monitoring is necessary to keep the concentration within the therapeutic range (typically 10 to 20 mcg/mL total phenytoin) and manage potential toxicity.


Q: Does the generic version of Hidantin work exactly the same as the brand name?

Generic versions of the medication are required to meet regulatory bioequivalence criteria, meaning they contain the same active ingredient and work similarly. However, documented cases have suggested that changes in the manufacturer may be associated with changes in the drug’s blood concentrations in some individuals.


Q: If I miss a dose of Hidantin, what is the generally accepted advice?

General patient information describes a common approach where a missed dose is taken if remembered quickly, or skipped if it is near the next scheduled dose time. Taking a double dose is generally advised against. A healthcare provider can provide the appropriate guidance for individual circumstances.


Q: What is the research evidence for using Hidantin to manage nerve pain?

While the drug is primarily approved for the treatment of seizures, official patient information leaflets sometimes mention that the medication is also used to treat specific types of nerve pain, such as pain in the nerves of the face. This application is supported by the drug's ability to stabilize nerve cell excitability.


Q: How long does Hidantin stay in the system after the last dose is taken?

Official pharmacokinetic information indicates that the average plasma half-life of Phenytoin in adults is approximately 22 hours, though this can vary widely, ranging from 7 to 42 hours. The half-life is the time it takes for the concentration of the drug in the blood to decrease by half.


Q: Is it common for Hidantin to cause changes in hair growth or texture?

Official safety information and patient resources list changes in hair growth as a possible side effect. This may include increased growth of body and facial hair, known as hirsutism. This effect is a documented part of the drug’s safety profile.


Q: Can Hidantin interact with common over-the-counter pain relievers like ibuprofen or aspirin?

Regulatory information indicates that Hidantin may interact with nonsteroidal anti-inflammatory drugs (NSAIDs), which include common pain relievers like ibuprofen and aspirin. Concurrent use may alter blood levels of both medications. These interactions may necessitate close monitoring or evaluation for dose adjustments.


Q: What is the official purpose of the Black Box Warning on the Hidantin label?

The FDA’s Boxed Warning highlights the serious risk of cardiovascular events, including severe hypotension (low blood pressure) and cardiac arrhythmias (irregular heart rhythms), that can occur during the intravenous (IV) administration of the drug. The warning details strict administration rate constraints for the IV formulation, noting that rapid administration can lead to serious heart-related events.


Q: Does Hidantin affect sleep patterns or cause insomnia?

Official patient safety information lists both drowsiness and difficulty sleeping (insomnia) as possible central nervous system side effects of the medication.


Q: Are there known interactions between Hidantin and herbal supplements?

Official sources and drug interaction resources confirm that this medication is known to interact with certain herbal supplements. Specific examples, such as St. John's wort, ginkgo, and glutamine, are noted to potentially change the drug's effectiveness or increase the risk of side effects.


Q: What is the difference in how quickly the liquid form of Hidantin works versus the tablet form?

Official regulatory documents acknowledge that the rate at which the medication is absorbed can differ between the various oral formulations, including capsules, chewable tablets, and the oral suspension. When a patient switches between different oral forms, such changes are managed through assessment for potential dose adjustment and additional blood level monitoring to maintain consistent therapeutic effects.


Q: Are there official warnings about combining Hidantin with antidepressant medications?

Official drug information suggests that combining Hidantin with certain antidepressant medications, such as sertraline, can alter the blood levels and effects of both drugs. Managing this interaction may involve clinical evaluation for dose adjustments or frequent monitoring.


Q: Does Hidantin affect laboratory test results for other conditions?

Official safety information indicates that the drug can affect laboratory test results. Specifically, it has been noted that Phenytoin can cause blood glucose levels to rise (hyperglycemia). The potential influence on these systems is managed through monitoring of blood glucose, liver function, and kidney function.


Q: What level of blood concentration is considered the 'therapeutic range' for Hidantin?

The therapeutic range is the concentration of the medication in the bloodstream needed to achieve the desired effect without causing toxicity. For total phenytoin, this range is generally accepted by medical guidance as 10 to 20 mcg/mL in adults and children. The clinical response is used to assess the most appropriate level for an individual.


Q: Is it true that a sudden illness, like the flu, can change how Hidantin works?

While regulatory sources do not specifically list general viral illnesses like the flu, they do warn that common cold and flu medications can interact with Hidantin. These interactions may be associated with altered blood levels of the drug, which could potentially lead to side effects.


Q: What does official data say about the likelihood of an allergic reaction to Hidantin?

Official safety data highlights the risk of rare but serious reactions, including Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS) and DRESS syndrome. Additionally, a known hypersensitivity to the drug is listed as an absolute contraindication. These severe reactions represent the most critical allergic-type risks described in official documents.


Q: Can you be allergic to the non-active ingredients in the Hidantin formulation?

While contraindications primarily focus on hypersensitivity to the active ingredient (phenytoin), some official package inserts acknowledge that non-active ingredients can be a concern for specific groups. For example, individuals with galactose intolerance are noted as requiring caution with the capsule formulation.


Q: Does the manufacturing source of generic Hidantin have an impact on its consistency?

Regulatory documents require all manufacturers to produce bioequivalent formulations. However, documented cases have suggested that changes in the manufacturer may be associated with changes in the drug’s blood concentrations in some individuals.


Q: Is it described in official sources that Hidantin can be used for migraine prevention?

Official patient education materials sometimes mention that the drug is used to treat migraine headaches. This application is an example of the drug's use beyond its primary approved purpose of managing seizures.

How should Hidantin be stored and disposed of?

How to Store and Dispose of Hidantin (Phenytoin)

Hidantin must be stored according to official regulatory requirements to maintain its stability. The medication requires storage at controlled room temperature, generally defined as 20 C to 25 C (68 F to 77 F).

Storage Protection

Formulation Required Protection
Capsules/Tablets Store in tight, light-resistant containers; protect from moisture.
Oral Suspension Protect from freezing and light.

All forms of this medication must be stored out of the reach of children, as this is a mandatory safety instruction. Unused or expired Hidantin must be disposed of using an authorized drug take-back program. If such a program is not available, the medicine should be mixed with undesirable material, placed in a sealed container, and discarded in the household trash; the medicine should not be flushed down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hidantin found in:

A-Z Index: